• The PLATINUM-Truveta retrospective cohort analysis compared the effectiveness of semaglutide 2.4 mg and resmetirom on liver enzymes and cardiometabolic markers in people with MASH
• New post hoc data from ESSENCE examines changes in liver related parameters with semaglutide 2.4 mg vs placebo in people with MASH and a BMI below 27 kg/m²
• Four posters, including one oral presentation, on investigational efruxifermin research and new analyses from the phase 2b SYMMETRY trial in compensated MASH cirrhosis

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Oct. 28, 2026 /PRNewswire/ -- Novo Nordisk today announced that 12 new abstracts on semaglutide real-world and clinical data will be presented at the American Association for the Study of Liver Diseases congress, The Liver Meeting® 2026, from November 5-9 in Denver, Colorado.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.